Literature DB >> 26629286

Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer.

Loretta Fala.   

Abstract

Entities:  

Year:  2015        PMID: 26629286      PMCID: PMC4665059     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN: 1942-2962


× No keyword cloud information.
  5 in total

1.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

Authors:  C Durante; N Haddy; E Baudin; S Leboulleux; D Hartl; J P Travagli; B Caillou; M Ricard; J D Lumbroso; F De Vathaire; M Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2006-05-09       Impact factor: 5.958

2.  Annual financial impact of well-differentiated thyroid cancer care in the United States.

Authors:  Carrie C Lubitz; Chung Y Kong; Pamela M McMahon; Gilbert H Daniels; Yufei Chen; Konstantinos P Economopoulos; G Scott Gazelle; Milton C Weinstein
Journal:  Cancer       Date:  2014-01-30       Impact factor: 6.860

3.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Authors:  Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

4.  The clinical and economic burden of a sustained increase in thyroid cancer incidence.

Authors:  Briseis Aschebrook-Kilfoy; Rebecca B Schechter; Ya-Chen Tina Shih; Edwin L Kaplan; Brian C-H Chiu; Peter Angelos; Raymon H Grogan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-05-15       Impact factor: 4.254

5.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

  5 in total
  5 in total

1.  Fournier's gangrene during lenvatinib treatment: A case report.

Authors:  Martina Barone; Giorgio Grani; Valeria Ramundo; Tiziana Garritano; Cosimo Durante; Rosa Falcone
Journal:  Mol Clin Oncol       Date:  2020-04-10

2.  Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.

Authors:  Christine Dierks; Jochen Seufert; Konrad Aumann; Juri Ruf; Claudius Klein; Selina Kiefer; Michael Rassner; Melanie Boerries; Andreas Zielke; Paul la Rosee; Philipp Tobias Meyer; Matthias Kroiss; Christian Weißenberger; Tilmann Schumacher; Patrick Metzger; Harald Weiss; Constantin Smaxwil; Katharina Laubner; Justus Duyster; Nikolas von Bubnoff; Cornelius Miething; Oliver Thomusch
Journal:  Thyroid       Date:  2021-04-15       Impact factor: 6.568

Review 3.  Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies.

Authors:  Valentina Comunanza; Federico Bussolino
Journal:  Front Cell Dev Biol       Date:  2017-12-07

4.  Synthesis and characterization of some novel diaryl urea derivatives bearing quinoxalindione moiety.

Authors:  Sedighe Sadeghian-Rizi; Ghadamali Khodarahmi; Amirhossein Sakhteman; Ali Jahanian-Najafabadi; Mahboubeh Rostami; Mahmoud Mirzaei; Farshid Hassanzadeh
Journal:  Res Pharm Sci       Date:  2018-02

Review 5.  The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis.

Authors:  Xiaobo Li; Yong Li; Weijin Lu; Minfeng Chen; Wencai Ye; Dongmei Zhang
Journal:  Cells       Date:  2019-12-10       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.